Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the initiation of a clinical trial to evaluate the
combination of the company’s investigational anti-PD-1 immunotherapy,
MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor,
pazopanib, in advanced renal cell carcinoma.
... read more